Central Bank & Trust Co. Has $1.73 Million Position in Zoetis Inc. $ZTS

Central Bank & Trust Co. grew its holdings in Zoetis Inc. (NYSE:ZTS) by 54.3% in the fourth quarter, Holdings Channel.com reports. The firm owned 13,714 shares of the company’s stock after purchasing an additional 4,827 shares during the period. Central Bank & Trust Co.’s holdings in Zoetis were worth $1,725,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Halbert Hargrove Global Advisors LLC raised its position in Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after buying an additional 144 shares during the period. Global Wealth Strategies & Associates acquired a new stake in Zoetis during the 4th quarter worth about $25,000. KERR FINANCIAL PLANNING Corp purchased a new position in Zoetis during the 3rd quarter valued at about $31,000. Holos Integrated Wealth LLC acquired a new position in shares of Zoetis in the 4th quarter valued at about $32,000. Finally, Board of the Pension Protection Fund acquired a new position in shares of Zoetis in the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the subject of several research reports. Leerink Partners restated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Morgan Stanley set a $160.00 target price on shares of Zoetis in a research report on Thursday, December 18th. Piper Sandler reissued a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Barclays started coverage on shares of Zoetis in a report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price target on the stock. Finally, William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Six research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $152.91.

Zoetis Trading Down 0.3%

Shares of NYSE ZTS opened at $115.31 on Tuesday. The stock has a market cap of $48.68 billion, a price-to-earnings ratio of 19.15, a PEG ratio of 1.77 and a beta of 0.95. The business has a 50 day simple moving average of $124.15 and a 200 day simple moving average of $130.02. Zoetis Inc. has a 52 week low of $114.36 and a 52 week high of $172.23. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. Zoetis’s dividend payout ratio is 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.